Table 3 Clinical evolution and outcome
Patient number | Clinical data during vaccination | Radiological evolution | Therapy-induced clinical effect | Follow-up period after surgery (months) | Treatment after vaccination, current status |
|---|---|---|---|---|---|
1 | Peritumoral oedema with grade IV neurotoxicity, responding to steroids | Peritumoral oedema from V2; SD during 7–8 weeks, later PD | Yes | 7 | DOD at 05-2001 |
2 | Nihil | — | Yes | 36 | CCR |
3 | Morning stiffness after V5 | Transient contrast enhancement after V5 | Yes | 35 | CCR |
4 | Nihil | Relapse after 3 months | No | 12 | Surgery, chemotherapy; DOD at 07-2002 |
5 | At moment of V3: thrombocytes=72 000 μl−1 | Relapse after 3 months | No | 23 | Temozolomid; Ommaya reservoir and repetitive punctions of cystic fluid; DOD at 11-2003 |
6 | Subdural hygroma after surgery, anaemia after V3: Hb=9 g dl−1 | CCR of primary tumour; progression and later on regression of metastatic lesion | Yes | 7 | Abruption of further vaccination; † at 09-2002 |
7 | Nihil | PD after 2 months | No | 8 | DOD at 10-2002 |
8 | Nihil | Immediate progression | No | 4 | DOD at 08-2002 |
9 | Night sweating after V4 | PD after 2 months | No | 7 | Chemotherapy; DOD at 12-2002 |
10 | Meningismus after V3 | PD after 4 months | No | 9 | Chemotherapy; DOD at 02-2003 |
11 | Nihil | PD after 16 months | No | 17 | DOD at 11-2003 |
12 | Nihil | Relapse after 3 months | No | 14 | Chemotherapy; DOD at 11-2003 |
